+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032- Product Image
Sale

Oral Medications for Multiple Sclerosis Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124774
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Medications for Multiple Sclerosis Market is projected to reach USD 6.76 Billion in 2026. It is expected to continue growing at a CAGR of 7.31%, reaching USD 10.44 Billion by 2032.

Oral Medications for Multiple Sclerosis: Executive Overview

Oral medications have become an important component of multiple sclerosis (MS) care, offering alternatives to injectable and infused disease-modifying therapies. Their use is shaped by disease phenotype, treatment goals, safety monitoring, adherence considerations, reimbursement, and clinician familiarity. Key oral therapy classes include sphingosine-1-phosphate receptor modulators, fumarates, and teriflunomide, while oral corticosteroids and symptomatic medicines serve different clinical purposes. Treatment decisions require individualized assessment because efficacy, contraindications, monitoring requirements, and reproductive or infection-related risks differ across products.

How MS Treatment Is Shifting Toward Individualized Oral Care

MS management is shifting from a one-size-fits-all escalation model toward earlier, individualized selection of disease-modifying therapy. Clinicians increasingly weigh disease activity, MRI findings, comorbidities, age, pregnancy plans, infection risk, laboratory results, route-of-administration preferences, and adherence capacity. Oral treatment can reduce injection burden and may improve convenience, but convenience does not remove the need for ongoing laboratory, ophthalmic, cardiovascular, or infection-related monitoring where clinically indicated. Safety communications, label updates, generic availability, and payer requirements also influence prescribing patterns.

Artificial Intelligence Is Strengthening Diagnosis, Monitoring, and Treatment Support

Artificial intelligence is contributing to MS care through image analysis, lesion detection, disease-progression assessment, and clinical decision support. Machine-learning tools can help identify subtle changes across MRI studies and organize longitudinal clinical data, although performance depends on data quality, validation, workflow integration, and appropriate clinician oversight. AI may also support adherence-risk identification, adverse-event surveillance, and trial recruitment. It does not replace neurologist judgment: treatment selection still requires contextual interpretation of symptoms, imaging, comorbidities, patient preferences, and approved prescribing information.

Regional Insights: Access and Care Pathways Differ Across Six Major Regions

North America generally combines broad specialist capacity with substantial payer and authorization complexity. Europe benefits from established neurology networks and regulatory coordination, but reimbursement and national treatment pathways vary. Asia-Pacific includes highly developed systems alongside settings where specialist access, MRI capacity, and affordability remain uneven. Latin America faces differences in public coverage, private access, and continuity of treatment. The Middle East shows concentrated specialist services in some countries and access constraints in others, while Africa continues to contend with diagnostic delays, limited neurologist availability, and uneven access to advanced monitoring. Across all regions, reliable diagnosis, medication supply, pharmacovigilance, and patient support are central implementation priorities.

Group Insights: Policy Alignment and Health-System Capacity Shape Adoption

The ASEAN group reflects wide variation in regulatory maturity, specialist availability, and reimbursement, making regional harmonization valuable. BRICS countries span large and diverse populations with differing public procurement, domestic manufacturing, and specialist-care capabilities. The European Union benefits from shared regulatory structures but retains national differences in reimbursement and clinical implementation. G7 health systems generally have strong research and monitoring infrastructure, though affordability and access controls remain important. GCC countries often combine advanced tertiary care with centralized procurement and cross-border referral patterns. NATO members represent diverse health systems, yet interoperability, emergency preparedness, and continuity of chronic care are common considerations. These groupings should be interpreted as policy and system contexts rather than uniform treatment markets.

Country Insights: National Differences Influence Oral MS Treatment Use

Australia and Canada combine specialist expertise with geographically dispersed populations and public reimbursement considerations. The United States offers extensive therapeutic choice but requires navigation of formulary controls, prior authorization, and out-of-pocket exposure. Brazil and Mexico face pronounced differences between public and private access, while India requires attention to affordability, specialist distribution, and diagnostic capacity. China is expanding specialist and hospital capabilities, with access shaped by regulatory and reimbursement pathways. Japan and South Korea have advanced healthcare infrastructure, with local clinical practice and coverage rules influencing uptake. France, Germany, Italy, Spain, and the United Kingdom rely on strong neurology services but differ in assessment, commissioning, and reimbursement mechanisms. Russia’s MS care is influenced by regional healthcare variation, medicine access, and continuity challenges. Across these countries, patient monitoring and sustained adherence remain as important as initial prescription.

Actions for Leaders: Improve Safe Access, Adherence, and Evidence Generation

Industry leaders should align oral-therapy strategies with local clinical guidelines, reimbursement rules, and monitoring capacity rather than assuming uniform adoption. Practical priorities include simplifying patient education, strengthening adherence and persistence support, improving transparent safety communication, and developing services that help clinicians manage laboratory and follow-up requirements. Evidence programs should reflect diverse populations, real-world treatment sequencing, comorbidities, pregnancy considerations, and long-term disability outcomes. Partnerships with neurologists, pharmacists, patient organizations, payers, and public-health systems can help identify access barriers while maintaining appropriate use. Digital and AI-enabled tools should be introduced only with clinical validation, privacy safeguards, explainability, and clear accountability.

Research Methodology: Evidence-Based Synthesis of Clinical and Health-System Factors

This executive summary uses a structured qualitative synthesis of established MS treatment principles, regulatory and guideline considerations, health-system characteristics, and technology trends relevant to oral medications. Regional, group, and country observations are framed around access, diagnosis, reimbursement, monitoring, specialist capacity, and care continuity. Claims are limited to broadly documented clinical and policy patterns, with no market estimates, sizing, shares, or forecasts. Interpretation should be updated against current prescribing information, national guidelines, reimbursement decisions, safety communications, and peer-reviewed evidence because treatment standards and access conditions change over time.

Conclusion: Oral MS Therapy Requires Coordinated, Patient-Centered Implementation

Oral medications provide meaningful flexibility within modern MS treatment, but their value depends on appropriate patient selection, reliable monitoring, informed shared decision-making, and sustained access. Regional and national differences in specialist care, reimbursement, diagnostics, and medicine supply will continue to shape outcomes. Leaders who combine evidence-based clinical support with adherence services, responsible digital innovation, and locally responsive access strategies will be better positioned to improve safe and continuous MS care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Medications for Multiple Sclerosis Market, by Molecule
7.1. Introduction
7.2. Dimethyl Fumarate
7.3. Diroximel Fumarate
7.4. Fingolimod
7.5. Monomethyl Fumarate
7.6. Ozanimod
7.7. Ponesimod
7.8. Siponimod
7.9. Teriflunomide
8. Oral Medications for Multiple Sclerosis Market, by Drug Class
8.1. Introduction
8.2. Dihydroorotate Dehydrogenase Inhibitors
8.3. Fumarates
8.3.1. Dimethyl Fumarate
8.3.2. Diroximel Fumarate
8.3.3. Monomethyl Fumarate
8.4. Sphingosine 1 Phosphate Receptor Modulators
8.4.1. Fingolimod
8.4.2. Ozanimod
8.4.3. Ponesimod
8.4.4. Siponimod
9. Oral Medications for Multiple Sclerosis Market, by Indication
9.1. Introduction
9.2. Clinically Isolated Syndrome
9.3. Relapsing Remitting Multiple Sclerosis
9.4. Secondary Progressive Multiple Sclerosis Active
10. Oral Medications for Multiple Sclerosis Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Later Line
10.4. Second Line
11. Oral Medications for Multiple Sclerosis Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Tablet
12. Oral Medications for Multiple Sclerosis Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
12.4. Specialty Pharmacy
13. Oral Medications for Multiple Sclerosis Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Oral Medications for Multiple Sclerosis Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Oral Medications for Multiple Sclerosis Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Acorda Therapeutics, Inc.
17.3. Bayer AG
17.4. Biogen Inc.
17.5. Bristol-Myers Squibb Company
17.6. Clene Nanomedicine, Inc.
17.7. Eisai Co., Ltd.
17.8. F. Hoffmann-La Roche Ltd.
17.9. GlaxoSmithKline plc
17.10. Immensa Biotherapeutics, Inc.
17.11. Immunic, Inc.
17.12. Janssen Pharmaceuticals, Inc.
17.13. Merck KGaA
17.14. Mitsubishi Tanabe Pharma Corporation
17.15. Novartis AG
17.16. Oryzon Genomics, S.A.
17.17. Pfizer Inc.
17.18. Sanofi
17.19. Teva Pharmaceutical Industries Ltd.
17.20. Viatris Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oral Medications for Multiple Sclerosis Market, Years Considered for the Study
FIGURE 2. Global Oral Medications for Multiple Sclerosis Market, Research Design
FIGURE 3. Global Oral Medications for Multiple Sclerosis Market, Research Framework
FIGURE 4. Global Oral Medications for Multiple Sclerosis Market, Data Triangulation
FIGURE 5. Global Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2025 vs 2032 (%)
FIGURE 7. Global Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oral Medications for Multiple Sclerosis Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Oral Medications for Multiple Sclerosis Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 13. Global Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 15. Global Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oral Medications for Multiple Sclerosis Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Oral Medications for Multiple Sclerosis Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Oral Medications for Multiple Sclerosis Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oral Medications for Multiple Sclerosis Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Oral Medications for Multiple Sclerosis Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Oral Medications for Multiple Sclerosis Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oral Medications for Multiple Sclerosis Market Segmentation & Coverage
TABLE 2. Global Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 4. Global Dimethyl Fumarate Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Dimethyl Fumarate Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Dimethyl Fumarate Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Diroximel Fumarate Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Diroximel Fumarate Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Diroximel Fumarate Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Fingolimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Fingolimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Fingolimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Monomethyl Fumarate Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Monomethyl Fumarate Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Monomethyl Fumarate Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Ozanimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Ozanimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Ozanimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Ponesimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Ponesimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Ponesimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Siponimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Siponimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Siponimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Teriflunomide Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Teriflunomide Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Teriflunomide Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 29. Global Dihydroorotate Dehydrogenase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Dihydroorotate Dehydrogenase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Dihydroorotate Dehydrogenase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Fumarates Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Fumarates Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Fumarates Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Dimethyl Fumarate Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Dimethyl Fumarate Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Dimethyl Fumarate Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Diroximel Fumarate Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Diroximel Fumarate Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Diroximel Fumarate Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Monomethyl Fumarate Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Monomethyl Fumarate Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Monomethyl Fumarate Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Sphingosine 1 Phosphate Receptor Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Sphingosine 1 Phosphate Receptor Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Sphingosine 1 Phosphate Receptor Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Fingolimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Fingolimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Fingolimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Ozanimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Ozanimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Ozanimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Ponesimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Ponesimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Ponesimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Siponimod Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Siponimod Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Siponimod Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 60. Global Clinically Isolated Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Clinically Isolated Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Clinically Isolated Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Relapsing Remitting Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Relapsing Remitting Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Relapsing Remitting Multiple Sclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Secondary Progressive Multiple Sclerosis Active Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Secondary Progressive Multiple Sclerosis Active Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Secondary Progressive Multiple Sclerosis Active Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 70. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Later Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Later Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Later Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 80. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 87. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. North America Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. North America Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 108. North America Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 109. North America Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 110. North America Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 111. North America Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. North America Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 113. North America Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 114. North America Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. Latin America Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Latin America Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 117. Latin America Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 118. Latin America Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 119. Latin America Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 120. Latin America Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. Latin America Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 122. Latin America Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 123. Latin America Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Europe Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Europe Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 126. Europe Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 127. Europe Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 128. Europe Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 129. Europe Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. Europe Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 131. Europe Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 132. Europe Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. Middle East Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Middle East Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 135. Middle East Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 136. Middle East Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 137. Middle East Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 138. Middle East Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 139. Middle East Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 140. Middle East Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 141. Middle East Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. Africa Oral Medications for Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Africa Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 144. Africa Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 145. Africa Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 146. Africa Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 147. Africa Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. Africa Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 149. Africa Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 150. Africa Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. Global Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 154. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 155. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 156. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 157. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 159. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 160. ASEAN Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. GCC Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. GCC Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 163. GCC Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 164. GCC Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 165. GCC Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 166. GCC Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. GCC Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 168. GCC Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 169. GCC Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. European Union Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. European Union Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 172. European Union Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 173. European Union Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 174. European Union Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 175. European Union Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. European Union Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 177. European Union Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 178. European Union Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. BRICS Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. BRICS Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 181. BRICS Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 182. BRICS Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 183. BRICS Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 184. BRICS Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 185. BRICS Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 186. BRICS Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 187. BRICS Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. G7 Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. G7 Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 190. G7 Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 191. G7 Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 192. G7 Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 193. G7 Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. G7 Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 195. G7 Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 196. G7 Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. NATO Oral Medications for Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. NATO Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 199. NATO Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 200. NATO Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 201. NATO Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 202. NATO Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. NATO Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 204. NATO Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 205. NATO Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. Global Oral Medications for Multiple Sclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 207. United States Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 208. United States Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 209. United States Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 210. United States Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 211. United States Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 212. United States Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. United States Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 214. United States Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 215. United States Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Canada Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 217. Canada Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 218. Canada Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 219. Canada Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 220. Canada Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 221. Canada Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. Canada Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 223. Canada Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 224. Canada Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Mexico Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 226. Mexico Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 227. Mexico Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 228. Mexico Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 229. Mexico Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 230. Mexico Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. Mexico Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 232. Mexico Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 233. Mexico Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Brazil Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 235. Brazil Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 236. Brazil Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 237. Brazil Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 238. Brazil Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 239. Brazil Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Brazil Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 241. Brazil Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. Brazil Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. United Kingdom Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 244. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 245. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 246. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 247. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 248. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 249. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 250. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 251. United Kingdom Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Germany Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 253. Germany Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 254. Germany Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 255. Germany Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 256. Germany Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 257. Germany Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. Germany Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 259. Germany Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 260. Germany Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. France Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 262. France Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 263. France Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 264. France Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 265. France Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 266. France Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. France Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 268. France Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 269. France Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. Russia Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 271. Russia Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 272. Russia Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 273. Russia Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 274. Russia Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 275. Russia Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 276. Russia Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 277. Russia Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 278. Russia Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. Italy Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 280. Italy Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 281. Italy Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 282. Italy Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 283. Italy Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 284. Italy Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 285. Italy Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 286. Italy Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 287. Italy Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. Spain Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 289. Spain Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 290. Spain Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 291. Spain Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 292. Spain Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 293. Spain Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 294. Spain Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 295. Spain Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 296. Spain Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 297. China Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 298. China Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 299. China Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 300. China Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 301. China Oral Medications for Multiple Sclerosis Market Size, by Sphingosine 1 Phosphate Receptor Modulators, 2017-2032 (USD Million)
TABLE 302. China Oral Medications for Multiple Sclerosis Market Size, by Indication, 2017-2032 (USD Million)
TABLE 303. China Oral Medications for Multiple Sclerosis Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 304. China Oral Medications for Multiple Sclerosis Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 305. China Oral Medications for Multiple Sclerosis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 306. India Oral Medications for Multiple Sclerosis Market Size, 2017-2032 (USD Million)
TABLE 307. India Oral Medications for Multiple Sclerosis Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 308. India Oral Medications for Multiple Sclerosis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 309. India Oral Medications for Multiple Sclerosis Market Size, by Fumarates, 2017-2032 (USD Million)
TABLE 310. India Oral Medications for Multiple Sclero

Companies Mentioned

  • AbbVie Inc.
  • Acorda Therapeutics, Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Clene Nanomedicine, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Immensa Biotherapeutics, Inc.
  • Immunic, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Oryzon Genomics, S.A.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Multiple Sclerosis Drugs Market Report 2026 - Product Image

Multiple Sclerosis Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
Multiple Sclerosis Drugs - Global Strategic Business Report - Product Image

Multiple Sclerosis Drugs - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From
Multiple Sclerosis Market - Global Forecast 2026-2032 - Product Image

Multiple Sclerosis Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Relapsing-Remitting Multiple Sclerosis - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Relapsing-Remitting Multiple Sclerosis - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.